KR101666692B1 - 세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법 - Google Patents

세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법 Download PDF

Info

Publication number
KR101666692B1
KR101666692B1 KR1020117012368A KR20117012368A KR101666692B1 KR 101666692 B1 KR101666692 B1 KR 101666692B1 KR 1020117012368 A KR1020117012368 A KR 1020117012368A KR 20117012368 A KR20117012368 A KR 20117012368A KR 101666692 B1 KR101666692 B1 KR 101666692B1
Authority
KR
South Korea
Prior art keywords
cells
cell
delete delete
ido
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117012368A
Other languages
English (en)
Korean (ko)
Other versions
KR20110123721A (ko
Inventor
더크 뷔셰
올가 데 라 로사
엘레우테리오 롬바르도
Original Assignee
셀레릭스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀레릭스 에스에이 filed Critical 셀레릭스 에스에이
Publication of KR20110123721A publication Critical patent/KR20110123721A/ko
Application granted granted Critical
Publication of KR101666692B1 publication Critical patent/KR101666692B1/ko
Assigned to 다케다 파머수티컬 컴패니 리미티드 reassignment 다케다 파머수티컬 컴패니 리미티드 권리의 전부이전등록 Assignors: 타이제닉스, 에스.에이.유.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117012368A 2008-11-07 2009-11-06 세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법 Active KR101666692B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0820397.8A GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
GB0820397.8 2008-11-07
PCT/EP2009/064788 WO2010052313A1 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Publications (2)

Publication Number Publication Date
KR20110123721A KR20110123721A (ko) 2011-11-15
KR101666692B1 true KR101666692B1 (ko) 2016-10-17

Family

ID=40139550

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117012368A Active KR101666692B1 (ko) 2008-11-07 2009-11-06 세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법

Country Status (9)

Country Link
US (1) US9012220B2 (https=)
EP (1) EP2361261B1 (https=)
JP (1) JP5745419B2 (https=)
KR (1) KR101666692B1 (https=)
AU (1) AU2009312700B2 (https=)
CA (1) CA2742698C (https=)
ES (1) ES2479540T3 (https=)
GB (1) GB0820397D0 (https=)
WO (1) WO2010052313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
ES2479565T1 (es) * 2011-03-11 2014-08-20 Tigenix, S.A.U. Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos
EP3985106A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population
EP3985105A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029310A2 (en) * 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1252897A4 (en) 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
EP1501918A4 (en) * 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
ES2368152T3 (es) * 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
US20090155311A1 (en) * 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
US20080155704A1 (en) * 2006-12-22 2008-06-26 King's College London Methods and Compositions for Determining in vivo Activity of BiP
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
WO2009155477A1 (en) * 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun. 168(1):1-8(1990.04.16.)*
Curr. Opin. Pharmacol. 6(4):435-441(2006.08.)*
NCBI Accession, GenBank X17998.1*
Stem Cells Dev. 17(4):681-693(2008.08.)*

Also Published As

Publication number Publication date
CA2742698C (en) 2017-04-18
WO2010052313A1 (en) 2010-05-14
EP2361261A1 (en) 2011-08-31
ES2479540T1 (es) 2014-08-20
EP2361261B1 (en) 2016-01-27
ES2479540T3 (es) 2016-05-20
US9012220B2 (en) 2015-04-21
JP2012507997A (ja) 2012-04-05
AU2009312700A1 (en) 2010-05-14
JP5745419B2 (ja) 2015-07-08
US20120064031A1 (en) 2012-03-15
KR20110123721A (ko) 2011-11-15
CA2742698A1 (en) 2010-05-14
AU2009312700B2 (en) 2014-06-26
GB0820397D0 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
KR102021982B1 (ko) Mnd 프로모터 키메라 항원 수용체
KR102445700B1 (ko) 안정한 슈도타입화된 렌티바이러스 입자 및 이의 용도
US20260108610A1 (en) Drug-Resistant Immune Cells and Methods of Use Thereof
US9850497B2 (en) Gene targeting methods and tools
US20210139935A1 (en) Methods of manufacturing car-t cells
CN106755092A (zh) GLCCI1基因基于Cre‑LoxP条件性基因敲除小鼠模型构建试剂盒及构建方法
KR20210046004A (ko) 조혈 세포의 유전자 변형 방법
KR20220095223A (ko) 조작된 조절 t 세포 생성
JP7825866B2 (ja) ミトコンドリア増強療法
KR20230010231A (ko) 생체내 형질도입을 위한 벡터 및 방법
KR101666692B1 (ko) 세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법
KR101354996B1 (ko) 임파구계 혈구계 세포에 유전자 도입을 위한 프로모터 및그의 이용 방법
AU2022312311A1 (en) Anti-EGFRviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition comprising said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptide
US20240093242A1 (en) Gene correction for scid-x1 in long-term hematopoietic stem cells
CN116322793A (zh) 改进的使用科卡尔包膜的t细胞转导用慢病毒载体的生成
RU2824194C2 (ru) Способы генной модификации гемопоэтических клеток
WO2023233176A1 (en) Novel human induced pluripotent stem cell line stably expressing a reporter
CN115161345A (zh) 高表达FRα的重组载体、重组细胞及其构建方法和用途
RU2799573C2 (ru) Химерные антигенные рецепторы с mnd-промотором
HK40050172A (en) Drug-resistant immune cells and methods of use thereof
CN115867663A (zh) 真核细胞中dna片段的维持、方法和用途
HK40102227A (zh) Omni-103 crispr核酸酶
CN115216492A (zh) 一种小鼠原发神经胶质瘤模型的制备方法及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110530

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141030

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151208

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160728

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20161010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20161010

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190917

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190917

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200928

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200928

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20210915

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20210915

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20220922

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20220922

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee